GW Pharmaceuticals PLC- (GWPH) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a sell rating to a hold rating in a report published on Wednesday.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

How to Become a New Pot Stock Millionaire

Several other research firms have also issued reports on GWPH. BidaskClub raised GW Pharmaceuticals PLC- from a hold rating to a buy rating in a report on Friday, December 22nd. Leerink Swann reissued a buy rating and set a $153.00 price target on shares of GW Pharmaceuticals PLC- in a report on Tuesday, January 23rd. Cantor Fitzgerald reissued a buy rating and set a $192.00 price target (down previously from $208.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, February 5th. Bank of America cut their price target on GW Pharmaceuticals PLC- from $154.00 to $149.00 and set a buy rating for the company in a report on Tuesday, February 6th. Finally, Goldman Sachs raised GW Pharmaceuticals PLC- from a neutral rating to a buy rating and set a $174.00 price target for the company in a report on Thursday, December 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $146.38.

Shares of GWPH stock opened at $116.01 on Wednesday. GW Pharmaceuticals PLC- has a fifty-two week low of $92.65 and a fifty-two week high of $143.37. The company has a current ratio of 11.44, a quick ratio of 11.34 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $3,313.24, a PE ratio of -13.84 and a beta of 2.63.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.03) by ($0.40). GW Pharmaceuticals PLC- had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. The company had revenue of $7.73 million for the quarter, compared to the consensus estimate of $2.18 million. equities research analysts expect that GW Pharmaceuticals PLC- will post -8.95 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its stake in shares of GW Pharmaceuticals PLC- by 2.6% in the third quarter. Janus Henderson Group PLC now owns 717,729 shares of the biopharmaceutical company’s stock worth $72,842,000 after acquiring an additional 18,194 shares during the period. Consonance Capital Management LP boosted its stake in shares of GW Pharmaceuticals PLC- by 12.2% in the fourth quarter. Consonance Capital Management LP now owns 675,492 shares of the biopharmaceutical company’s stock worth $89,172,000 after acquiring an additional 73,445 shares during the period. Alliancebernstein L.P. boosted its stake in shares of GW Pharmaceuticals PLC- by 18.0% in the fourth quarter. Alliancebernstein L.P. now owns 332,273 shares of the biopharmaceutical company’s stock worth $43,863,000 after acquiring an additional 50,780 shares during the period. Victory Capital Management Inc. boosted its stake in shares of GW Pharmaceuticals PLC- by 6.5% in the fourth quarter. Victory Capital Management Inc. now owns 261,390 shares of the biopharmaceutical company’s stock worth $34,506,000 after acquiring an additional 15,995 shares during the period. Finally, Deutsche Bank AG boosted its stake in shares of GW Pharmaceuticals PLC- by 233.5% in the fourth quarter. Deutsche Bank AG now owns 228,206 shares of the biopharmaceutical company’s stock worth $30,124,000 after acquiring an additional 159,783 shares during the period. 82.51% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “GW Pharmaceuticals PLC- (GWPH) Upgraded at Zacks Investment Research” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3296819/gw-pharmaceuticals-plc-gwph-upgraded-at-zacks-investment-research.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Liberum Capital Reiterates Hold Rating for Sports Direct
Liberum Capital Reiterates Hold Rating for Sports Direct
RWS  Rating Reiterated by Shore Capital
RWS Rating Reiterated by Shore Capital
WPP’s  Hold Rating Reiterated at Deutsche Bank
WPP’s Hold Rating Reiterated at Deutsche Bank
Berenberg Bank Raises Ten Entertainment Group  Price Target to GBX 310
Berenberg Bank Raises Ten Entertainment Group Price Target to GBX 310
Evonik Industries  Given a €27.00 Price Target by UBS Analysts
Evonik Industries Given a €27.00 Price Target by UBS Analysts
eMagin  Sees Large Decline in Short Interest
eMagin Sees Large Decline in Short Interest


© 2006-2018 Ticker Report. Google+.